| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Postural Orthostatic Tachycardia Syndrome | 26 | 2023 | 37 | 3.690 |
Why?
|
| Blood Pressure | 40 | 2021 | 526 | 3.640 |
Why?
|
| Spike Glycoprotein, Coronavirus | 9 | 2026 | 114 | 2.530 |
Why?
|
| Evolution, Molecular | 10 | 2026 | 350 | 2.260 |
Why?
|
| Hypotension, Orthostatic | 19 | 2019 | 27 | 2.250 |
Why?
|
| Baroreflex | 14 | 2019 | 22 | 2.090 |
Why?
|
| Recombination, Genetic | 7 | 2026 | 256 | 1.990 |
Why?
|
| Autonomic Nervous System Diseases | 16 | 2020 | 21 | 1.970 |
Why?
|
| Genome, Viral | 9 | 2025 | 144 | 1.840 |
Why?
|
| Chiroptera | 5 | 2025 | 17 | 1.790 |
Why?
|
| Heart Rate | 26 | 2021 | 331 | 1.770 |
Why?
|
| Phylogeny | 18 | 2025 | 388 | 1.650 |
Why?
|
| HIV-1 | 11 | 2026 | 706 | 1.640 |
Why?
|
| Immunity, Herd | 2 | 2024 | 2 | 1.530 |
Why?
|
| HIV Infections | 11 | 2026 | 955 | 1.490 |
Why?
|
| Posture | 12 | 2021 | 127 | 1.460 |
Why?
|
| Menstrual Cycle | 6 | 2021 | 83 | 1.400 |
Why?
|
| Humans | 162 | 2026 | 65140 | 1.280 |
Why?
|
| Genomics | 5 | 2025 | 384 | 1.270 |
Why?
|
| Anti-Mullerian Hormone | 5 | 2022 | 68 | 1.250 |
Why?
|
| Multiple System Atrophy | 7 | 2017 | 13 | 1.130 |
Why?
|
| Pure Autonomic Failure | 7 | 2018 | 8 | 1.080 |
Why?
|
| Autonomic Nervous System | 14 | 2016 | 35 | 1.050 |
Why?
|
| Computational Biology | 6 | 2021 | 367 | 1.010 |
Why?
|
| Sympathetic Nervous System | 13 | 2019 | 35 | 1.010 |
Why?
|
| Norepinephrine | 11 | 2021 | 106 | 0.990 |
Why?
|
| Pandemics | 9 | 2025 | 674 | 0.990 |
Why?
|
| Menopause | 4 | 2020 | 256 | 0.970 |
Why?
|
| Ovarian Follicle | 5 | 2022 | 39 | 0.950 |
Why?
|
| Terminology as Topic | 2 | 2026 | 144 | 0.910 |
Why?
|
| Tachycardia | 5 | 2012 | 28 | 0.900 |
Why?
|
| Immune Evasion | 4 | 2021 | 71 | 0.880 |
Why?
|
| Blood Volume | 5 | 2014 | 40 | 0.870 |
Why?
|
| Endemic Diseases | 1 | 2024 | 23 | 0.830 |
Why?
|
| Inhibins | 4 | 2020 | 50 | 0.810 |
Why?
|
| Kidney | 4 | 2017 | 451 | 0.810 |
Why?
|
| Hypertension | 12 | 2019 | 612 | 0.810 |
Why?
|
| Follicle Stimulating Hormone | 4 | 2020 | 86 | 0.810 |
Why?
|
| Benzhydryl Compounds | 4 | 2014 | 61 | 0.760 |
Why?
|
| Cross-Over Studies | 19 | 2021 | 164 | 0.740 |
Why?
|
| Coronavirus | 1 | 2022 | 14 | 0.710 |
Why?
|
| Mass Vaccination | 1 | 2021 | 8 | 0.690 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 213 | 0.680 |
Why?
|
| Female | 83 | 2026 | 34018 | 0.680 |
Why?
|
| Growth Differentiation Factor 9 | 6 | 2022 | 9 | 0.670 |
Why?
|
| Aging | 5 | 2020 | 771 | 0.670 |
Why?
|
| Adult | 57 | 2025 | 17358 | 0.660 |
Why?
|
| Cell Count | 1 | 2020 | 128 | 0.640 |
Why?
|
| DNA Viruses | 2 | 2019 | 16 | 0.620 |
Why?
|
| Infertility, Female | 2 | 2019 | 47 | 0.620 |
Why?
|
| Pain | 3 | 2007 | 399 | 0.620 |
Why?
|
| Fertilization in Vitro | 2 | 2019 | 83 | 0.610 |
Why?
|
| Mutation | 12 | 2026 | 2661 | 0.600 |
Why?
|
| Male | 66 | 2025 | 31047 | 0.580 |
Why?
|
| Bone Morphogenetic Protein 15 | 5 | 2022 | 8 | 0.570 |
Why?
|
| Wnt Proteins | 2 | 2016 | 104 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 180 | 0.560 |
Why?
|
| Angiotensin II | 3 | 2012 | 25 | 0.530 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.520 |
Why?
|
| Hemodynamics | 6 | 2016 | 251 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.510 |
Why?
|
| Vasoconstrictor Agents | 4 | 2019 | 70 | 0.510 |
Why?
|
| Drinking | 1 | 2017 | 14 | 0.510 |
Why?
|
| Middle Aged | 44 | 2025 | 18273 | 0.500 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2016 | 46 | 0.490 |
Why?
|
| Space Flight | 3 | 2016 | 20 | 0.480 |
Why?
|
| Viruses | 3 | 2022 | 81 | 0.480 |
Why?
|
| Animals | 25 | 2026 | 21345 | 0.480 |
Why?
|
| Solitary Nucleus | 1 | 2015 | 5 | 0.470 |
Why?
|
| Cyclohexanes | 1 | 2015 | 2 | 0.460 |
Why?
|
| Gene Deletion | 2 | 2014 | 312 | 0.460 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2015 | 10 | 0.460 |
Why?
|
| Triazoles | 2 | 2015 | 63 | 0.460 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2015 | 17 | 0.460 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 66 | 0.460 |
Why?
|
| Drug Resistance, Viral | 2 | 2015 | 160 | 0.450 |
Why?
|
| Natriuresis | 2 | 2013 | 7 | 0.450 |
Why?
|
| Young Adult | 17 | 2025 | 4809 | 0.450 |
Why?
|
| Receptors, CCR5 | 1 | 2015 | 59 | 0.450 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2015 | 61 | 0.440 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 450 | 0.440 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 3 | 2012 | 4 | 0.430 |
Why?
|
| Yohimbine | 3 | 2012 | 9 | 0.430 |
Why?
|
| Papillomavirus Vaccines | 3 | 2020 | 69 | 0.420 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2014 | 11 | 0.420 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 17 | 0.410 |
Why?
|
| Supine Position | 8 | 2019 | 34 | 0.410 |
Why?
|
| Insulin | 4 | 2017 | 695 | 0.410 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2013 | 5 | 0.410 |
Why?
|
| Liver | 2 | 2023 | 871 | 0.400 |
Why?
|
| Primary Dysautonomias | 2 | 2019 | 6 | 0.400 |
Why?
|
| Gene Dosage | 1 | 2013 | 72 | 0.400 |
Why?
|
| Vicia faba | 1 | 2013 | 4 | 0.390 |
Why?
|
| Pyridostigmine Bromide | 2 | 2019 | 5 | 0.370 |
Why?
|
| Syncope | 2 | 2016 | 42 | 0.370 |
Why?
|
| Sodium Chloride, Dietary | 2 | 2017 | 10 | 0.370 |
Why?
|
| Dopamine | 1 | 2013 | 108 | 0.370 |
Why?
|
| Propylamines | 4 | 2014 | 8 | 0.370 |
Why?
|
| Double-Blind Method | 9 | 2015 | 739 | 0.360 |
Why?
|
| Treatment Outcome | 17 | 2019 | 5792 | 0.350 |
Why?
|
| Sequence Alignment | 3 | 2026 | 300 | 0.350 |
Why?
|
| Catecholamines | 5 | 2019 | 31 | 0.350 |
Why?
|
| Host Specificity | 2 | 2021 | 11 | 0.340 |
Why?
|
| Amino Acid Sequence | 5 | 2026 | 1589 | 0.340 |
Why?
|
| Mice, Knockout | 4 | 2026 | 2157 | 0.340 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2022 | 22 | 0.340 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 2 | 2007 | 21 | 0.330 |
Why?
|
| Perioperative Care | 1 | 2012 | 87 | 0.330 |
Why?
|
| Pain Threshold | 2 | 2007 | 21 | 0.330 |
Why?
|
| History, 21st Century | 2 | 2024 | 179 | 0.320 |
Why?
|
| Pressoreceptors | 2 | 2009 | 4 | 0.320 |
Why?
|
| History, 20th Century | 2 | 2024 | 232 | 0.320 |
Why?
|
| Genotype | 5 | 2021 | 673 | 0.320 |
Why?
|
| Virology | 2 | 2021 | 13 | 0.310 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 4 | 2013 | 9 | 0.310 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 325 | 0.300 |
Why?
|
| Propranolol | 1 | 2009 | 22 | 0.300 |
Why?
|
| Adolescent | 12 | 2020 | 6297 | 0.300 |
Why?
|
| Fatigue Syndrome, Chronic | 4 | 2020 | 9 | 0.300 |
Why?
|
| Adrenergic Uptake Inhibitors | 4 | 2014 | 13 | 0.280 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 152 | 0.280 |
Why?
|
| RNA, Viral | 6 | 2021 | 266 | 0.270 |
Why?
|
| Antibodies, Neutralizing | 4 | 2022 | 217 | 0.270 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 134 | 0.270 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 15 | 0.270 |
Why?
|
| Fatigue | 2 | 2011 | 113 | 0.270 |
Why?
|
| Case-Control Studies | 10 | 2023 | 1141 | 0.260 |
Why?
|
| Plasma Volume | 1 | 2007 | 4 | 0.260 |
Why?
|
| Computer Simulation | 3 | 2026 | 483 | 0.250 |
Why?
|
| Administration, Oral | 6 | 2015 | 371 | 0.250 |
Why?
|
| Aged | 27 | 2020 | 14965 | 0.250 |
Why?
|
| Oocytes | 4 | 2022 | 201 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 856 | 0.250 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2024 | 62 | 0.250 |
Why?
|
| Simian Immunodeficiency Virus | 2 | 2024 | 84 | 0.240 |
Why?
|
| Viral Tropism | 2 | 2018 | 55 | 0.240 |
Why?
|
| Sodium Chloride | 1 | 2006 | 65 | 0.240 |
Why?
|
| Atomoxetine Hydrochloride | 5 | 2019 | 6 | 0.240 |
Why?
|
| Hemoglobins | 2 | 2011 | 136 | 0.240 |
Why?
|
| Phylogeography | 2 | 2025 | 6 | 0.240 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 2483 | 0.240 |
Why?
|
| Respiration | 2 | 2016 | 93 | 0.230 |
Why?
|
| Affect | 1 | 2007 | 131 | 0.230 |
Why?
|
| Midodrine | 2 | 2016 | 3 | 0.230 |
Why?
|
| Stromal Cells | 1 | 2026 | 78 | 0.230 |
Why?
|
| Adrenal Medulla | 1 | 2005 | 7 | 0.220 |
Why?
|
| Bacteriophages | 2 | 2024 | 66 | 0.220 |
Why?
|
| Metanephrine | 1 | 2004 | 1 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2026 | 71 | 0.220 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2015 | 130 | 0.220 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2005 | 50 | 0.220 |
Why?
|
| Public Health | 2 | 2024 | 186 | 0.220 |
Why?
|
| Prospective Studies | 11 | 2022 | 3308 | 0.220 |
Why?
|
| Biomarkers | 8 | 2022 | 1480 | 0.210 |
Why?
|
| Vagus Nerve | 2 | 2019 | 20 | 0.210 |
Why?
|
| Lysogeny | 1 | 2024 | 8 | 0.210 |
Why?
|
| Anemia | 1 | 2006 | 132 | 0.210 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2025 | 382 | 0.210 |
Why?
|
| Water | 2 | 2006 | 314 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2024 | 321 | 0.210 |
Why?
|
| Insulin Resistance | 3 | 2017 | 414 | 0.210 |
Why?
|
| Proteome | 1 | 2025 | 152 | 0.210 |
Why?
|
| Amino Acid Substitution | 2 | 2022 | 238 | 0.200 |
Why?
|
| Epitopes | 2 | 2022 | 291 | 0.200 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2023 | 23 | 0.200 |
Why?
|
| Neuropeptides | 1 | 2004 | 81 | 0.200 |
Why?
|
| Tilt-Table Test | 4 | 2015 | 11 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2026 | 274 | 0.200 |
Why?
|
| Bayes Theorem | 2 | 2021 | 125 | 0.200 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 3 | 0.200 |
Why?
|
| Models, Molecular | 2 | 2026 | 1162 | 0.200 |
Why?
|
| Adrenal Glands | 1 | 2023 | 35 | 0.190 |
Why?
|
| Renin | 2 | 2013 | 10 | 0.190 |
Why?
|
| Parkinson Disease | 2 | 2017 | 135 | 0.190 |
Why?
|
| Psychometrics | 1 | 2025 | 392 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2004 | 135 | 0.190 |
Why?
|
| Muscle, Skeletal | 4 | 2019 | 788 | 0.190 |
Why?
|
| Proteomics | 1 | 2025 | 293 | 0.190 |
Why?
|
| Hepatitis | 1 | 2023 | 58 | 0.190 |
Why?
|
| Sleep Wake Disorders | 2 | 2016 | 77 | 0.190 |
Why?
|
| Endometriosis | 1 | 2022 | 27 | 0.190 |
Why?
|
| Societies, Scientific | 2 | 2020 | 36 | 0.190 |
Why?
|
| Nitric Oxide | 2 | 2014 | 164 | 0.190 |
Why?
|
| Biology | 1 | 2023 | 25 | 0.190 |
Why?
|
| Dermatitis | 1 | 2022 | 27 | 0.190 |
Why?
|
| Host-Pathogen Interactions | 1 | 2025 | 279 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 81 | 0.180 |
Why?
|
| Hypovolemia | 3 | 2023 | 17 | 0.180 |
Why?
|
| Health Policy | 1 | 2024 | 191 | 0.180 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2017 | 13 | 0.180 |
Why?
|
| Vasopressins | 1 | 2002 | 15 | 0.180 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2021 | 5 | 0.180 |
Why?
|
| Caregivers | 1 | 2025 | 294 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2017 | 366 | 0.180 |
Why?
|
| Viruses, Unclassified | 1 | 2021 | 1 | 0.180 |
Why?
|
| Microbiota | 1 | 2024 | 169 | 0.180 |
Why?
|
| Classification | 1 | 2021 | 13 | 0.180 |
Why?
|
| Antihypertensive Agents | 3 | 2015 | 179 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 52 | 0.170 |
Why?
|
| Salmonella Phages | 1 | 2021 | 3 | 0.170 |
Why?
|
| Antigenic Variation | 1 | 2021 | 7 | 0.170 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 9 | 0.170 |
Why?
|
| Virus Physiological Phenomena | 1 | 2021 | 8 | 0.170 |
Why?
|
| Public Opinion | 1 | 2021 | 26 | 0.170 |
Why?
|
| Syncope, Vasovagal | 2 | 2011 | 8 | 0.170 |
Why?
|
| Base Sequence | 5 | 2021 | 1332 | 0.170 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 112 | 0.170 |
Why?
|
| Independent Living | 1 | 2021 | 55 | 0.170 |
Why?
|
| Cross Infection | 1 | 2022 | 164 | 0.170 |
Why?
|
| Exercise Tolerance | 2 | 2014 | 85 | 0.170 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 1979 | 0.170 |
Why?
|
| Receptors, Virus | 1 | 2021 | 73 | 0.160 |
Why?
|
| Salmonella | 1 | 2021 | 45 | 0.160 |
Why?
|
| Single-Blind Method | 6 | 2019 | 142 | 0.160 |
Why?
|
| Mammals | 1 | 2022 | 222 | 0.160 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2025 | 404 | 0.160 |
Why?
|
| Genetic Fitness | 1 | 2021 | 35 | 0.160 |
Why?
|
| Selection, Genetic | 1 | 2021 | 90 | 0.160 |
Why?
|
| Home Care Services | 1 | 2021 | 99 | 0.160 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 72 | 0.160 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2010 | 13 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Software | 2 | 2021 | 400 | 0.160 |
Why?
|
| Amino Acids | 1 | 2021 | 148 | 0.160 |
Why?
|
| Hormones | 2 | 2015 | 62 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2019 | 399 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 317 | 0.160 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2019 | 2 | 0.160 |
Why?
|
| Cytochrome b Group | 1 | 2019 | 20 | 0.160 |
Why?
|
| Virus Replication | 3 | 2021 | 323 | 0.150 |
Why?
|
| Phenotype | 1 | 2004 | 1233 | 0.150 |
Why?
|
| Astronauts | 2 | 2016 | 7 | 0.150 |
Why?
|
| Gonadotropins | 1 | 2019 | 14 | 0.150 |
Why?
|
| China | 1 | 2020 | 176 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 150 | 0.150 |
Why?
|
| Ovary | 3 | 2019 | 105 | 0.150 |
Why?
|
| Employment | 1 | 2021 | 132 | 0.150 |
Why?
|
| Virus Internalization | 2 | 2022 | 91 | 0.150 |
Why?
|
| Hyperventilation | 3 | 2016 | 7 | 0.150 |
Why?
|
| Papillomaviridae | 1 | 2019 | 59 | 0.150 |
Why?
|
| Apnea | 2 | 2016 | 33 | 0.150 |
Why?
|
| Luteal Cells | 1 | 2019 | 2 | 0.150 |
Why?
|
| Valsalva Maneuver | 2 | 2016 | 11 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2020 | 394 | 0.150 |
Why?
|
| Genetic Loci | 1 | 2019 | 116 | 0.150 |
Why?
|
| Pressure | 3 | 2015 | 78 | 0.150 |
Why?
|
| Circadian Rhythm | 3 | 2014 | 361 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 3485 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2018 | 208 | 0.140 |
Why?
|
| Activins | 1 | 2019 | 55 | 0.140 |
Why?
|
| Time Factors | 9 | 2019 | 3762 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 176 | 0.140 |
Why?
|
| Quality of Life | 3 | 2019 | 1260 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 101 | 0.140 |
Why?
|
| Protein Conformation | 1 | 2021 | 792 | 0.140 |
Why?
|
| Virus Diseases | 1 | 2019 | 117 | 0.140 |
Why?
|
| Sodium | 3 | 2013 | 60 | 0.140 |
Why?
|
| Polysomnography | 2 | 2016 | 60 | 0.140 |
Why?
|
| Disease Progression | 2 | 2024 | 1220 | 0.130 |
Why?
|
| Autonomic Denervation | 1 | 2017 | 2 | 0.130 |
Why?
|
| Splanchnic Nerves | 1 | 2017 | 3 | 0.130 |
Why?
|
| Hypotonic Solutions | 1 | 2017 | 7 | 0.130 |
Why?
|
| Reference Values | 3 | 2007 | 327 | 0.130 |
Why?
|
| Hematocrit | 2 | 2008 | 32 | 0.130 |
Why?
|
| Jugular Veins | 1 | 2017 | 28 | 0.130 |
Why?
|
| Blood Pressure Determination | 4 | 2019 | 39 | 0.130 |
Why?
|
| Lewy Body Disease | 1 | 2017 | 15 | 0.130 |
Why?
|
| Duodenum | 1 | 2017 | 41 | 0.130 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 21 | 0.130 |
Why?
|
| Hyperinsulinism | 1 | 2017 | 26 | 0.130 |
Why?
|
| Portal Vein | 1 | 2017 | 39 | 0.130 |
Why?
|
| Osmolar Concentration | 1 | 2017 | 91 | 0.130 |
Why?
|
| HIV | 2 | 2024 | 67 | 0.120 |
Why?
|
| Epinephrine | 2 | 2014 | 46 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2023 | 827 | 0.120 |
Why?
|
| Drinking Water | 1 | 2017 | 21 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 676 | 0.120 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2016 | 1 | 0.120 |
Why?
|
| Systole | 4 | 2017 | 109 | 0.120 |
Why?
|
| Splanchnic Circulation | 1 | 2016 | 16 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 274 | 0.120 |
Why?
|
| Action Potentials | 2 | 2007 | 113 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 863 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2016 | 30 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 118 | 0.120 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2016 | 34 | 0.120 |
Why?
|
| Dependovirus | 1 | 2023 | 751 | 0.120 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2016 | 5 | 0.120 |
Why?
|
| Epithelium | 1 | 2016 | 100 | 0.120 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 7 | 0.120 |
Why?
|
| Models, Animal | 1 | 2017 | 241 | 0.120 |
Why?
|
| Spironolactone | 1 | 2015 | 9 | 0.120 |
Why?
|
| Stroke Volume | 2 | 2015 | 342 | 0.120 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 20 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 152 | 0.120 |
Why?
|
| Caspase 8 | 1 | 2016 | 66 | 0.120 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2015 | 27 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 162 | 0.110 |
Why?
|
| United States | 6 | 2022 | 8093 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2017 | 169 | 0.110 |
Why?
|
| Virulence | 3 | 2021 | 199 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 43 | 0.110 |
Why?
|
| Patient Isolation | 1 | 2015 | 7 | 0.110 |
Why?
|
| Carotid Body Tumor | 1 | 2015 | 2 | 0.110 |
Why?
|
| Airway Resistance | 1 | 2015 | 8 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 175 | 0.110 |
Why?
|
| Inhalation | 1 | 2015 | 11 | 0.110 |
Why?
|
| Government Programs | 1 | 2015 | 19 | 0.110 |
Why?
|
| Glycosylation | 1 | 2015 | 138 | 0.110 |
Why?
|
| Neuronal Plasticity | 1 | 2016 | 153 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2014 | 6 | 0.110 |
Why?
|
| Caspases | 1 | 2016 | 176 | 0.110 |
Why?
|
| Ethanolamines | 1 | 2014 | 18 | 0.110 |
Why?
|
| Myosins | 1 | 2016 | 118 | 0.110 |
Why?
|
| Metoprolol | 1 | 2014 | 18 | 0.110 |
Why?
|
| Restraint, Physical | 1 | 2015 | 58 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2007 | 742 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 2757 | 0.110 |
Why?
|
| Placebo Effect | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 40 | 0.110 |
Why?
|
| Sinoatrial Node | 1 | 2014 | 3 | 0.110 |
Why?
|
| Tachycardia, Sinus | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2014 | 11 | 0.110 |
Why?
|
| Parasympathetic Nervous System | 1 | 2014 | 6 | 0.110 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2014 | 9 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 180 | 0.100 |
Why?
|
| Melatonin | 1 | 2014 | 66 | 0.100 |
Why?
|
| Rifampin | 1 | 2014 | 24 | 0.100 |
Why?
|
| Ganglia, Autonomic | 2 | 2010 | 2 | 0.100 |
Why?
|
| Ovarian Diseases | 1 | 2014 | 19 | 0.100 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 2 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Electrocardiography | 5 | 2016 | 554 | 0.100 |
Why?
|
| Algorithms | 3 | 2014 | 1050 | 0.100 |
Why?
|
| Placebos | 2 | 2014 | 73 | 0.100 |
Why?
|
| Age Factors | 2 | 2015 | 1586 | 0.100 |
Why?
|
| Integrases | 1 | 2014 | 41 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2016 | 422 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2016 | 413 | 0.100 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2013 | 2 | 0.100 |
Why?
|
| Levodopa | 1 | 2013 | 9 | 0.100 |
Why?
|
| Catechols | 1 | 2013 | 7 | 0.100 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 102 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2015 | 223 | 0.100 |
Why?
|
| HEK293 Cells | 3 | 2021 | 616 | 0.100 |
Why?
|
| United Kingdom | 3 | 2021 | 85 | 0.100 |
Why?
|
| Weightlessness Countermeasures | 2 | 2015 | 2 | 0.090 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2012 | 13 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 285 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 194 | 0.090 |
Why?
|
| Weightlessness | 2 | 2015 | 12 | 0.090 |
Why?
|
| Antidiuretic Agents | 1 | 2012 | 3 | 0.090 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2012 | 6 | 0.090 |
Why?
|
| Mice | 7 | 2026 | 11119 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2018 | 2620 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 460 | 0.090 |
Why?
|
| Shy-Drager Syndrome | 1 | 2012 | 2 | 0.090 |
Why?
|
| Acute Disease | 2 | 2023 | 663 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 513 | 0.090 |
Why?
|
| Hemostatics | 1 | 2012 | 27 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2019 | 3153 | 0.090 |
Why?
|
| Viral Load | 3 | 2018 | 230 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1163 | 0.090 |
Why?
|
| Interferons | 2 | 2022 | 74 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 124 | 0.090 |
Why?
|
| Blood Vessels | 2 | 2009 | 63 | 0.090 |
Why?
|
| Anesthesia | 1 | 2012 | 52 | 0.090 |
Why?
|
| Sympatholytics | 2 | 2014 | 5 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 2701 | 0.090 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2026 | 84 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2012 | 125 | 0.080 |
Why?
|
| Motor Activity | 1 | 2014 | 345 | 0.080 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 31 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 108 | 0.080 |
Why?
|
| Airway Management | 1 | 2012 | 60 | 0.080 |
Why?
|
| Mental Health Services | 1 | 2015 | 304 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 22 | 0.080 |
Why?
|
| Tennessee | 3 | 2015 | 17 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2011 | 29 | 0.080 |
Why?
|
| Sympathetic Fibers, Postganglionic | 2 | 2009 | 2 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2014 | 231 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6872 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2011 | 104 | 0.080 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 85 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 58 | 0.080 |
Why?
|
| Cardiovascular System | 3 | 2007 | 41 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 63 | 0.080 |
Why?
|
| Syndrome | 2 | 2007 | 180 | 0.080 |
Why?
|
| Respiratory Mechanics | 2 | 2009 | 56 | 0.080 |
Why?
|
| Drosophila Proteins | 1 | 2016 | 758 | 0.080 |
Why?
|
| Myasthenia Gravis | 1 | 2010 | 12 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2022 | 662 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 296 | 0.080 |
Why?
|
| Gorilla gorilla | 1 | 2009 | 3 | 0.080 |
Why?
|
| Carotid Body | 1 | 2009 | 1 | 0.070 |
Why?
|
| Diet | 1 | 2013 | 536 | 0.070 |
Why?
|
| Europe | 2 | 2020 | 199 | 0.070 |
Why?
|
| Aldosterone | 2 | 2023 | 18 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2010 | 288 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 120 | 0.070 |
Why?
|
| Hospitals | 2 | 2022 | 387 | 0.070 |
Why?
|
| Hospitalization | 2 | 2007 | 1392 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 509 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2009 | 140 | 0.070 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2009 | 60 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2018 | 247 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 1698 | 0.070 |
Why?
|
| Hyperalgesia | 1 | 2007 | 15 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 184 | 0.070 |
Why?
|
| Fluid Shifts | 1 | 2007 | 1 | 0.070 |
Why?
|
| Gravitation | 1 | 2007 | 10 | 0.070 |
Why?
|
| Endocrine Glands | 1 | 2007 | 7 | 0.070 |
Why?
|
| Fingers | 1 | 2007 | 49 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2026 | 1565 | 0.060 |
Why?
|
| Sleep Apnea, Central | 1 | 2007 | 8 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2007 | 35 | 0.060 |
Why?
|
| Exercise | 1 | 2014 | 964 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2007 | 145 | 0.060 |
Why?
|
| Electrodiagnosis | 1 | 2007 | 20 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 52 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1222 | 0.060 |
Why?
|
| Reproduction | 1 | 2007 | 98 | 0.060 |
Why?
|
| Plethysmography | 2 | 2016 | 11 | 0.060 |
Why?
|
| Internet | 1 | 2010 | 467 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2006 | 89 | 0.060 |
Why?
|
| Blood | 2 | 2018 | 31 | 0.060 |
Why?
|
| Dizziness | 1 | 2006 | 19 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 42 | 0.060 |
Why?
|
| Food, Formulated | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cell Line | 4 | 2021 | 2024 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 1113 | 0.060 |
Why?
|
| Evans Blue | 1 | 2006 | 1 | 0.060 |
Why?
|
| Serum Albumin, Radio-Iodinated | 1 | 2006 | 1 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2006 | 99 | 0.060 |
Why?
|
| Clonidine | 1 | 2006 | 25 | 0.060 |
Why?
|
| NIH 3T3 Cells | 2 | 2016 | 99 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 83 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 312 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 159 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1368 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2006 | 50 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2019 | 142 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 277 | 0.060 |
Why?
|
| Uganda | 1 | 2025 | 38 | 0.060 |
Why?
|
| Disease Reservoirs | 1 | 2025 | 10 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 643 | 0.060 |
Why?
|
| Diuresis | 1 | 2005 | 6 | 0.060 |
Why?
|
| Electrolytes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 767 | 0.060 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2004 | 9 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 196 | 0.050 |
Why?
|
| Child | 3 | 2023 | 4607 | 0.050 |
Why?
|
| Half-Life | 1 | 2004 | 81 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2026 | 183 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 463 | 0.050 |
Why?
|
| Progesterone | 3 | 2015 | 165 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 2102 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2004 | 83 | 0.050 |
Why?
|
| Risk Factors | 3 | 2014 | 5429 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2004 | 137 | 0.050 |
Why?
|
| Vesicular Biogenic Amine Transport Proteins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2004 | 2 | 0.050 |
Why?
|
| Gene Products, pol | 1 | 2003 | 9 | 0.050 |
Why?
|
| Symporters | 1 | 2004 | 16 | 0.050 |
Why?
|
| Estradiol | 3 | 2015 | 259 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2025 | 224 | 0.050 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 35 | 0.050 |
Why?
|
| Scotland | 1 | 2023 | 9 | 0.050 |
Why?
|
| Helper Viruses | 1 | 2023 | 5 | 0.050 |
Why?
|
| Papio | 1 | 2003 | 21 | 0.050 |
Why?
|
| HLA-DRB1 Chains | 1 | 2023 | 16 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2004 | 342 | 0.050 |
Why?
|
| Immunity | 1 | 2024 | 107 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 702 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2014 | 414 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1559 | 0.050 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2003 | 8 | 0.050 |
Why?
|
| Committee Membership | 1 | 2022 | 8 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2003 | 28 | 0.050 |
Why?
|
| Neuroglia | 1 | 2003 | 81 | 0.050 |
Why?
|
| Adrenergic Fibers | 1 | 2002 | 1 | 0.050 |
Why?
|
| HIV-2 | 1 | 2002 | 23 | 0.050 |
Why?
|
| Life Change Events | 1 | 2003 | 66 | 0.050 |
Why?
|
| Coinfection | 1 | 2023 | 59 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 92 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2025 | 962 | 0.050 |
Why?
|
| Health Planning | 1 | 2022 | 32 | 0.050 |
Why?
|
| Follicular Phase | 2 | 2015 | 15 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 5614 | 0.050 |
Why?
|
| Luteal Phase | 2 | 2015 | 28 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 1784 | 0.050 |
Why?
|
| Coronaviridae | 1 | 2021 | 1 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2014 | 602 | 0.040 |
Why?
|
| tau Proteins | 1 | 2003 | 210 | 0.040 |
Why?
|
| Protein Prenylation | 1 | 2021 | 6 | 0.040 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2021 | 19 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 110 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2023 | 192 | 0.040 |
Why?
|
| Economics, Nursing | 1 | 2021 | 1 | 0.040 |
Why?
|
| Viroids | 1 | 2021 | 1 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 39 | 0.040 |
Why?
|
| Genetic Drift | 1 | 2021 | 15 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 2188 | 0.040 |
Why?
|
| Refugees | 1 | 2003 | 75 | 0.040 |
Why?
|
| Zoonoses | 1 | 2021 | 9 | 0.040 |
Why?
|
| 5' Untranslated Regions | 1 | 2021 | 28 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 101 | 0.040 |
Why?
|
| Genes, Viral | 1 | 2021 | 57 | 0.040 |
Why?
|
| Retroelements | 1 | 2021 | 44 | 0.040 |
Why?
|
| Alleles | 1 | 2023 | 453 | 0.040 |
Why?
|
| Infection Control | 1 | 2022 | 103 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 27 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2021 | 57 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2023 | 222 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2021 | 130 | 0.040 |
Why?
|
| Ovarian Reserve | 1 | 2021 | 9 | 0.040 |
Why?
|
| Sweating | 2 | 2012 | 27 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 122 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 81 | 0.040 |
Why?
|
| International Cooperation | 1 | 2021 | 87 | 0.040 |
Why?
|
| Universities | 1 | 2022 | 168 | 0.040 |
Why?
|
| Codon | 1 | 2021 | 59 | 0.040 |
Why?
|
| Salmonella Infections | 1 | 2021 | 41 | 0.040 |
Why?
|
| Malnutrition | 1 | 2021 | 40 | 0.040 |
Why?
|
| Immunoassay | 1 | 2021 | 71 | 0.040 |
Why?
|
| Spain | 1 | 2020 | 32 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2015 | 497 | 0.040 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 410 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 336 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2020 | 34 | 0.040 |
Why?
|
| Sleep | 2 | 2016 | 240 | 0.040 |
Why?
|
| Glycine | 1 | 2020 | 48 | 0.040 |
Why?
|
| Gene Expression | 1 | 2024 | 852 | 0.040 |
Why?
|
| DNA Replication | 1 | 2022 | 247 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 1015 | 0.040 |
Why?
|
| Travel | 1 | 2020 | 44 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2021 | 125 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 2061 | 0.040 |
Why?
|
| Biological Evolution | 1 | 2021 | 128 | 0.040 |
Why?
|
| Plasma Exchange | 2 | 2010 | 24 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 128 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2021 | 316 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 1630 | 0.040 |
Why?
|
| Income | 1 | 2021 | 169 | 0.040 |
Why?
|
| Superovulation | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2019 | 35 | 0.040 |
Why?
|
| Follicular Fluid | 1 | 2019 | 15 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2021 | 191 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 169 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 72 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 657 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 60 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Oocyte Retrieval | 1 | 2019 | 14 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 90 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2007 | 1556 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 730 | 0.040 |
Why?
|
| Homeostasis | 1 | 2002 | 379 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 641 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 195 | 0.040 |
Why?
|
| Models, Biological | 1 | 2024 | 1192 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 335 | 0.040 |
Why?
|
| Serotyping | 1 | 2018 | 52 | 0.040 |
Why?
|
| Virus Cultivation | 1 | 2018 | 18 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 21 | 0.030 |
Why?
|
| Ecology | 1 | 2018 | 14 | 0.030 |
Why?
|
| Adaptation, Biological | 1 | 2018 | 19 | 0.030 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2018 | 9 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2018 | 19 | 0.030 |
Why?
|
| Linear Models | 2 | 2011 | 405 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 875 | 0.030 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 38 | 0.030 |
Why?
|
| Nevada | 1 | 2017 | 2 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 76 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2018 | 75 | 0.030 |
Why?
|
| Vertebrates | 1 | 2018 | 42 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2019 | 209 | 0.030 |
Why?
|
| Multigene Family | 1 | 2018 | 106 | 0.030 |
Why?
|
| Nitroglycerin | 2 | 2008 | 11 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2017 | 39 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 190 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 202 | 0.030 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 70 | 0.030 |
Why?
|
| Droxidopa | 1 | 2017 | 1 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 90 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 149 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 174 | 0.030 |
Why?
|
| Protein Binding | 1 | 2021 | 1640 | 0.030 |
Why?
|
| Demography | 2 | 2010 | 178 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 2016 | 30 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 20 | 0.030 |
Why?
|
| Tidal Volume | 1 | 2016 | 41 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2009 | 111 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 292 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 27 | 0.030 |
Why?
|
| Dextrans | 1 | 2016 | 45 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2293 | 0.030 |
Why?
|
| Telemedicine | 1 | 2021 | 362 | 0.030 |
Why?
|
| Wings, Animal | 1 | 2016 | 28 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2016 | 81 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 33 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 128 | 0.030 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2015 | 14 | 0.030 |
Why?
|
| Cameroon | 1 | 2015 | 3 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 178 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2007 | 94 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 240 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 162 | 0.030 |
Why?
|
| Suction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Stroop Test | 1 | 2015 | 8 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 801 | 0.030 |
Why?
|
| New York | 1 | 2015 | 144 | 0.030 |
Why?
|
| Nebivolol | 1 | 2014 | 1 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2003 | 822 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 257 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2014 | 9 | 0.030 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2014 | 3 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 99 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2015 | 51 | 0.030 |
Why?
|
| Anaerobic Threshold | 1 | 2014 | 12 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 43 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2014 | 14 | 0.030 |
Why?
|
| Vasodilation | 1 | 2014 | 36 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 588 | 0.030 |
Why?
|
| Parasympatholytics | 1 | 2014 | 7 | 0.030 |
Why?
|
| Executive Function | 1 | 2015 | 68 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2016 | 238 | 0.030 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 663 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 374 | 0.030 |
Why?
|
| Periodicity | 1 | 2014 | 46 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2014 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 868 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 71 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 137 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 363 | 0.030 |
Why?
|
| Electric Countershock | 1 | 2014 | 105 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2014 | 39 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 753 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 213 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2014 | 105 | 0.020 |
Why?
|
| Attention | 1 | 2015 | 151 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2014 | 136 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2015 | 489 | 0.020 |
Why?
|
| Orthostatic Intolerance | 1 | 2012 | 2 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2013 | 8 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2013 | 18 | 0.020 |
Why?
|
| Captopril | 1 | 2012 | 8 | 0.020 |
Why?
|
| Losartan | 1 | 2012 | 19 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2013 | 45 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 23 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 139 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 257 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 583 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 542 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 1422 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 1693 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 992 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 485 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 94 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1008 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2016 | 714 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 273 | 0.020 |
Why?
|
| Postural Balance | 1 | 2012 | 67 | 0.020 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 34 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 559 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2011 | 48 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1419 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 367 | 0.020 |
Why?
|
| Medication Systems | 1 | 2010 | 17 | 0.020 |
Why?
|
| Rituximab | 1 | 2010 | 89 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2010 | 69 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 33 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2010 | 184 | 0.020 |
Why?
|
| Electromyography | 1 | 2010 | 99 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 319 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 7 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 135 | 0.020 |
Why?
|
| Voriconazole | 1 | 2007 | 5 | 0.020 |
Why?
|
| Testicular Hormones | 1 | 2007 | 11 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2007 | 16 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 897 | 0.020 |
Why?
|
| Neck | 1 | 2007 | 46 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2007 | 42 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 122 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2007 | 101 | 0.020 |
Why?
|
| DNA Breaks | 1 | 2006 | 8 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 734 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 195 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2006 | 47 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2007 | 145 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 125 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2007 | 189 | 0.010 |
Why?
|
| Artifacts | 1 | 2006 | 126 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 195 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 296 | 0.010 |
Why?
|
| Romania | 1 | 2003 | 2 | 0.010 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2003 | 4 | 0.010 |
Why?
|
| Synucleins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Pons | 1 | 2003 | 15 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
| Monkey Diseases | 1 | 2003 | 7 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2003 | 21 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2003 | 38 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 1274 | 0.010 |
Why?
|
| Somalia | 1 | 2003 | 10 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cerebellum | 1 | 2003 | 94 | 0.010 |
Why?
|
| Proviruses | 1 | 2002 | 27 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 158 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 339 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 301 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 147 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 611 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 2002 | 50 | 0.010 |
Why?
|
| World Health Organization | 1 | 2002 | 35 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 283 | 0.010 |
Why?
|
| Androgens | 1 | 2002 | 66 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 896 | 0.010 |
Why?
|
| Neurons | 1 | 2006 | 933 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 428 | 0.010 |
Why?
|
| Prevalence | 1 | 2003 | 1445 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 1656 | 0.010 |
Why?
|
| Heart Failure | 1 | 2002 | 957 | 0.010 |
Why?
|